Show simple item record

Genética, HLA-B27 y espondilitis anquilosante: 40 años

dc.contributoren-US
dc.contributores-ES
dc.creatorCastro-Santos, Patricia; Universidad Autónoma de Chile
dc.creatorGutiérrez, Miguel A; Pontificia Universidad Católica de Chile
dc.creatorDíaz-Peña, Roberto; Universidad Autónoma de Chile
dc.date2014-09-12
dc.date.accessioned2019-11-11T18:26:18Z
dc.date.available2019-11-11T18:26:18Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/3313
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/110621
dc.descriptionAnkylosing spondylitis (AS) is a prototypical inflammatory disease of the locomotor system affecting axial skeleton. It is part of the general group of spondyloarthopathies (SpA). Its strong association with histocompatibility antigen HLA-B27 is known since 1973. However, HLA-B27 contribution to AS genetic risk is approximately16%. Therefore, other genes are necessarily involved in the pathogenesis of the disease. Genomic development and the possibility of making genome wide screening have contributed enormously to the study of the disease. In this paper, we describe the actual knowledge about AS genetic risk, which has contributed to understand the influence of HLA-B27 on the etiology and pathogenesis of the disease. We also intend to foresee how these findings will result in an improvement of patients’ quality of life.en-US
dc.descriptionAnkylosing spondylitis (AS) is a prototypical inflammatory disease of the locomotor system affecting axial skeleton. It is part of the general group of spondyloarthopathies (SpA). Its strong association with histocompatibility antigen HLA-B27 is known since 1973. However, HLA-B27 contribution to AS genetic risk is approximately16%. Therefore, other genes are necessarily involved in the pathogenesis of the disease. Genomic development and the possibility of making genome wide screening have contributed enormously to the study of the disease. In this paper, we describe the actual knowledge about AS genetic risk, which has contributed to understand the influence of HLA-B27 on the etiology and pathogenesis of the disease. We also intend to foresee how these findings will result in an improvement of patients’ quality of life.es-ES
dc.formatapplication/unknown
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/3313/505
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/3313/12585
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/3313/13488
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/3313/14616
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/3313/14639
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/3313/14640
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/3313/13489
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/3313/15728
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/3313/15729
dc.sourceRevista Médica de Chile; Vol. 142, núm. 9 (2014): SEPTIEMBRE 2014es-ES
dc.source0034-9887
dc.subjectGenetic predisposition to disease; HLA-B27 antigen; Spondylitis, ankylosingen-US
dc.subjectGenetic predisposition to disease; HLA-B27 antigen; Spondylitis, ankylosinges-ES
dc.titleGENETICS OF ANKYLOSING SPONDYLITISen-US
dc.titleGenética, HLA-B27 y espondilitis anquilosante: 40 añoses-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record